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Abstract
Background: The transcription factor SOX2, which is involved in the induction of pluripotent stem cells and
contributes to colorectal carcinogenesis, is associated with a poor prognosis in colon cancer (CC). Furthermore,
SOX2 is a repressor of the transcriptional activity of b-catenin in vitro. Since the majority of CC develop via an
activation of the Wnt/b-catenin signalling pathway, indicated by nuclear expression of b-catenin, we wanted to
investigate the expression patterns of SOX2 and b-catenin and correlate them with the occurrence of lymph node
and distant metastases as indicators of malignant progression.
Methods: The expression of SOX2 and b-catenin was investigated in a case control study utilizing a matched pair
collection (N = 114) of right-sided CCs with either corresponding distant metastases (N = 57) or without distant
spread (N = 57) by applying immunohistochemistry.
Results: Elevated protein expression of SOX2 significantly correlated with the presence of lymph node- (p = 0.006)
and distant metastases (p = 0.022). Nuclear b-catenin expression correlated significantly only with distant
metastases (p = 0.001). Less than 10% of cases showed a coexpression of high levels of b-catenin and SOX2. The
positivity for both markers was also associated with a very high risk for lymph-node metastases (p = 0.007) and
distant spread (p = 0.028).
Conclusion: We demonstrated that increased expression of either SOX2 or nuclear b-catenin are associated with
distant metastases in right-sided CC. Additionally, SOX2 is also associated with lymph-node metastases. These data
underline the importance of stemness-associated markers for the identification of CC with high risk for distant
spread.
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Background
Colon cancer (CC) is one of the most common human
malignancies and one of the major causes of cancer
related death worldwide [1]. About 60-80% of CCs
develop on the basis of a dysregulation of the Wnt/b-
catenin signalling pathway triggered in most cases by
mutations in the tumour suppressor gene APC (adeno-
matous polyposis coli) which is indicated by an accumu-
lation of b-catenin in the tumour cells [2-6]. By
immunohistochemistry it was shown that accumulation
of nuclear b-catenin correlated with the expression of b-
catenin target genes which are the drivers of the hall-
marks of cancer [7-12]. Thus, nuclear expression of b-
catenin is an indicator of active Wnt/b-catenin signal-
ling and expectedly nuclear b-catenin is associated with
tumour progression and poor prognosis in CC [13,14].
The transcription factor SOX2 is involved together with
c-Myc, KLF4 and Oct3/4 in the induction and mainte-
nance of pluripotent stem cells [15-18]. Recently it was
demonstrated, that SOX2 is also expressed in human CCs.
Similar to the expression of nuclear b-catenin, high SOX2
expression was associated with a poor prognosis,
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CC [19,20]. In contrast, SOX2 was also shown to repress
the transcriptional activity of the b-catenin/TCF complex
in vitro using TOP-flash assays and thus, repressing the
expression of TCF target genes [18,21,22]. Thus, SOX2
directly induces malignant progression of CCs and indir-
ectly represses it at the same time via suppression of b-
catenin activity. Currently it is unknown if SOX2 and b-
catenin are coexpressed in CCs and if a coexpression has
an influence on the progression. Finally, we wanted to
clarify, if the poorer outcome of CCs with high SOX2
expression is associated with an increased occurrence of
distant metastases, which is known to be the best predic-
tor for an unfavourable course of tumour diseases [19,20].
Therefore, we employed a case control collection of
human CCs with or without distant metastases applying
immunohistochemistry.
Methods
Tissue collection
Formalin fixed-paraffin embedded (FFPE) samples of
right-sided CCs from 114 patients that underwent cura-
tive surgical tumour resection at the Ludwig-Maximi-
lians-Universität (LMU) München between 1994 and
2005 were recovered from the archives of the Institute
of Pathology. The corresponding clinico-pathological
datasets were obtained from the Munich Cancer Regis-
try (MCR, Tumorzentrum München) (Table 1). For sta-
tistical reasons the collection was highly selected in the
form of a two-armed case-control study. One arm of the
collection consisted of CCs with synchronous liver
metastases, where metastasis was diagnosed by clinical
imaging or liver biopsy. The other arm of the collection
was represented by CCs without distant metastases at
t h et i m eo fd i a g n o s i sa n dw i t had i s e a s ef r e es u r v i v a lo f
at least 5 years after primary surgical resection to
exclude the development of metastases. Patients in both
arms were matched with respect to tumour grade
(according to WHO 2000), T stage (according to UICC
2009), and tumour localization (right side), resulting in
57 matched pairs. The study was performed according
to the recommendations of the local ethics committee
of the Medical Faculty of the LMU München.
Immunohistochemistry
All immunohistochemical stainings were done using 5
μm serial tissue sections of FFPE tumour samples. For
SOX2 specific immunohistochemistry first a heat-
induced epitope retrieval was done applying Epitope
Retrieval Solution (Novocastra, Leica Biosystems, United
Kingdom) before adding primary SOX2 specific rabbit
monoclonal antibody (1:50, SOX2 clone D6D9, Cell Sig-
nalling Technology, Danvers, MA) for 60 min at room
temperature. Thereafter, a development step was
introduced by adding detection-system (AEC Solution,
Invitrogen, Carlsbad, CA) and subsequently substrate-
chromogen containing AEC + system (DAKO, Ger-
many) according to the respective manufacturer’s proto-
cols. Finally, slides were counterstained using
Hematoxylin (Vector Laboratories, Burlingame, CA). To
control for unspecific binding of antibodies, isotype con-
trols were included. Normal stomach tissues with a well
described SOX2 staining pattern were used as the posi-
tive controls [23].
For the detection of b-catenin prediluted anti-b-cate-
nin mouse monoclonal antibody (ready to use, clone 14;
Ventana Medical Systems, Oro Valley, AZ) was used as
the primary antibody. Staining was done employing a
Ventana Benchmark XT autostainer using the XT Ultra-
View diaminobenzidine kit (Ventana Medical Systems)
following the manufacturer’s instructions.
Scoring of Immunohistochemistry
Evaluation of SOX2 immunostaining was done by two
observers (JN, FB) separately for the nucleus and the
cytoplasm. The results for nuclear staining were evalu-
ated for both, percentage and intensity of stained nuclei.
Intensity values were categorized as follows: no staining
- 0, weak - 1, moderate - 2, and strong - 3. When less
than 10% of cells were stained and/or the intensity was
missing (0) or weak (1), immunostaining was reported
to be negative [24]. The cytoplasm of cancerous colon
t i s s u es h o w e dn o n eo ro n l yw e a ks t a i n i n gf o rS O X 2 .
Therefore, since SOX2 is known to be a nuclear tran-
scription factor, cytoplasmic staining was not considered
for further statistical analysis.
Results of the b-catenin specific immunohistochemis-
try were also evaluated by two observers (JN, LK) sepa-
rately for the subcellular localization (cytoplasm and
nucleus). For nuclear b-catenin expression the quantity
of stained tumour cells throughout the whole tumour
but not the intensity of staining was considered. The
score for nuclear b-catenin expression was as follows:
negative - 0, < 30% - 1+, 30-60% - 2+, > 60% positive
cells - 3+. For cytoplasmic b-catenin expression the
intensity of specific staining was analysed and graded
into no - 0, weak - 1, moderate - 2 or strong cytoplas-
mic staining - 3. For subsequent statistical analysis the
cases were classified into low (scores 0 and 1) and high
grade (scores 2 and 3) extent for nuclear and cytoplas-
mic protein expression, respectively.
Statistics
Significance of correlations of the immunhistochemical
analyses were calculated using the c
2-test using SPSS v.
18.0 (SPSS Inc., Chicago, IL). For all tests a two-sided
a-error of less than 5% (p < 0.05) was considered statis-
tically significant.
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To investigate the expression patterns of SOX2 and b-
catenin in CC and to correlate these with the occur-
rence of metastases serial sections of 114 patients either
with metastases (N = 57) or without metastases and a
disease free survival of more than 5 years (N = 57) was
subjected to immunohistochemistry (Figure 1). Based on
the immunohistochemical score published by Park et al.,
a total of 21.1% of tumours showed nuclear SOX2
expression [24]. Expression of SOX2 correlated signifi-
cantly with lymph node metastases (p = 0.006), distant
metastases (p = 0.022) and histopathological tumour
grade (p = 0.043) according to WHO. No correlations
with tumour size (according to UICC), gender, or age
were found (Table 1). Absence of SOX2 expression was
associated with an advanced T-category (T3 - T4) but
reduced rates of locoregional- and distant spread and
lower histopathological tumour grades (G2 - G3; Table
1). In cases with low SOX2 but high b-catenin expres-
sion a higher rate of distant metastases could be
obtained (Table 2).
In 83 cases adjacent normal colonic tissue was avail-
able. Of these only four cases (4.8%) showed nuclear
expression within the stem cell niche of the colonic
crypts (Figure 2). No correlation of the expression pat-
terns of SOX2 in the normal and cancerous tissue could
be obtained, respectively.
Strong nuclear b-catenin expression was found in
33.3% of cases (N = 38) and correlated significantly with
the occurrence of distant metastases (p = 0.001), but not
with lymph node metastases, tumour stage, histopatho-
logical tumour grade, gender, or patient’s age (Table 1).
High levels of cytoplasmic protein expression of b-cate-
nin (N = 104; 91.2%) correlated only with the age of
patients. No correlation with patients’ gender, tumour
size, nodal status, distant spread or tumour grade
emerged (Table 1).
Combined high scores of SOX2 and nuclear b-catenin
expression were present in 8 of 114 cases (7.0%), thus
representing about one third of all SOX2 positive cases.
In this subgroup a significant correlation with nodal sta-
tus (100% showed lymph-node metastases, p = 0.02) and
distant spread (seven of eight cases (87.5%) showed
Table 1 Clinico-pathological variables and correlations with SOX2 and b-catenin protein expression in the matched
case-control collection of 114 CC patients. OR = odds ratio, CI = 95% confidence interval, Percent-values are given in
parentheses.
Characteristic Total (%) SOX-2 OR (CI) p b-catenin
(cytoplasmic)
OR (CI) p b-catenin
(nuclear)
OR (CI) p
high low high low high low
All patients 114 (100) 24 (21.1) 90 (78.9) 104 (91.2) 10 (8.8) 38 (33.3) 76 (66.7)
Age (median. 66.5) years
≤ 66 57 (50) 11 (9.6) 46 (40.4) 1.2 0.646 56 (49.1) 1 (0.9) 0.1 0.008 22 (19.3) 35 (30.7) 0.6 0.23
≥67 57 (50) 13 (11.4) 44 (38.6) (0.5-3.0) 48 (42.1) 9 (7.9) (0.01-0.8) 16 (14.0) 41 (36.0) (0.3-1.4)
Gender
Male 58 (50.9) 15 (13.2) 43 (37.7) 1.8 0.20 54 (47.4) 4 (3.5) 1.6 0.471 22 (19.3) 36 (31.6) 1.5 0.29
Female 56 (49.1) 9 (7.9) 47 (41.2) (0.7-4.6) 50 (43.9) 6 (5.3) (0.4-6.1) 16 (14.0) 40 (35.1) (0.7-3.4)
Tumor size (UICC)
T1 2 (1.8) 0 (0) 2 (1.8) - 0.280 2 (1.8) 0 (0) - 0.662 1 (0.9) 1 (0.9) - 0.607
T2 10 (8.8) 0 (0) 10 (8.8) 10 (8.8) 0 (0) 2 (1.8) 8 (7.0)
T3 86 (75.4) 21 (18.4) 65 (57.0) 77 (67.5) 9 (7.9) 31 (27.2) 55 (48.2)
T4 16 (14) 3 (2.6) 13 (11.4) 15 (13.2) 1 (0.9) 4 (3.5) 12 (10.5)
Nodal status
N0 52 (45.6) 5 (4.4) 47 (41.2) 4.2 0.006 49 (43.0) 3 (2.6) 0.5 0.299 15 (13.2) 37 (32.5) 1.5 0.35
N+ 62 (54.4) 19 (16.7) 43 (37.7) (1.4 - 12.1) 55 (48.2) 7 (6.1) (0.1-2.0) 23 (20.2) 39 (34.2) (0.7-3.2)
Metastasis (liver)
M0 57 (50) 7 (6.1) 50 (43.9) 3.0 0.022 52 (45.6) 5 (4.4) 1.0 1.0 11 (9.6) 46 (40.4) 3.8 0.001
M1 57 (50) 17 (14.9) 40 (35.1) (1.1-3.0) 52 (45.6) 5 (4.4) (0.3-3.7) 27 (23.7) 30 (26.3) (1.6-8.7)
Tumor grade (WHO)
G2 44 (38.6) 7 (6.1) 37 (32.5) - 0.043 43 (37.7) 1 (0.9) - 0.265 16 (14.0) 28 (24.6) - 0.567
G3 66 (57.9) 15 (13.2) 51 (44.7) 58 (50.9) 8 (7.0) 21 (18.4) 45 (39.5)
G4 4 (3.5) 2 (1.8) 2 (1.8) 3 (2.6) 1 (0.9) 1 (0.9) 3 (2.6)
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SOX2 and nuclear b-catenin expression was associated
with a reduced rate of distant metastases (only 33.3% of
these patients showed distant spread). No impact on the
frequency of lymph-node metastases could be derived in
this group of CC patients (Table 3).
Nevertheless, no correlation between SOX2 expression
and nuclear or cytoplasmic b-catenin protein levels with
Figure 1 Immunohistochemical staining of SOX2 (A and B) and b-catenin (C - F) in colonic adenocarcinoma (400-fold magnification).
CC with absence of SOX2 expression (A). Normal gastric mucosa was used as the positive control (insert). Tumours with presence of moderate
or strong nuclear protein expression of SOX2 in more than 10% of tumour cells were classified as SOX2 positive (B). Tumour cells with absence
(C) or presence (D) of nuclear b-catenin accumulation were classified as b-catenin low or b-catenin high, respectively. Weak (1+) and strong (3+)
cytoplasmic staining for b-catenin are shown in (E) and (F), respectively.
Table 2 Correlation of combined protein expression scores of SOX2 and nuclear b-catenin expression with lymph-node
metastases and distant spread. Percent-values are given in parentheses.
Nodal status Distant metastases
Protein expression profile N0 N+ p M0 M1 p
SOX2 and b-catenin low 32 (28.1) 28 (24.6) 0.02 40 (35.1) 20 (17.5) 0.001
SOX2 low and b-catenin high 15 (13.2) 15 (13.2) 10 (8.8) 20 (17.5)
SOX2 high and b-catenin low 5 (4.4) 11 (9.6) 6 (5.3) 10 (8.8)
SOX2 and b-catenin high 0 (0) 8 (7.0) 1 (0.9) 7 (6.1)
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b-catenin: p = 1.0; OR = 1.0, 95% CI = 0.4-2.6 and
SOX2 versus cytoplasmic b-catenin: p = 0.932; OR =
1.1, 95% CI = 0.2-5.4).
Discussion
In our two armed, matched collection of CCs we
demonstrated that high levels of both SOX2 and nuclear
b-catenin expression, respectively, were associated
significantly with metastatic disease. This observation
might explain the association of SOX2 protein expres-
sion with poorer prognosis and reduced overall survival
in CC, reported in the literature [19,20]. Lymph node
and distant metastases are both independent prognostic
factors correlating with poor survival in CC [25].
Patients with node-negative CCs (UICC stage I/II) have
a 5 year survival exceeding 75%, whereas patients with
node-positive disease only have a 5 year survival rate of
less than 50% [26]. Similar, patients with synchronous-
or metachronous liver metastases reveal 5 year survival
rates following liver resection ranging between 25% and
55% whereas for non-operated patients this rate lies
between 0% and 5% [27].
The highest rate of lymph node- and distant metas-
tases could be obtained in the group of CC with com-
bined scores of high SOX2 and high b-catenin
expression, whereas tumours with low or absent expres-
sion of both markers were associated with a reduced
risk for loco-regional- and distant spread. SOX2 nega-
t i v ec a s e sw i t hh i g hn u c l e a rb-catenin expression
showed higher rates of distant metastases but no asso-
ciation with the nodal status. Since nuclear b-catenin is
involved in epithelial-mesenchymal transition (EMT)
and stem cell formation during embryonic development,
the combination of EMT and stem cell competence dur-
ing malignant progression of CC, both regulated by b-
catenin, may result in “migrating tumour stem cells”,
driving tumour invasion and metastases [6,9]. b-catenin
is considered to be one of the driving forces for the
initiation and maintenance of colorectal cancer stem
cells (CSCs). In addition, SOX2 is an inducer of
embryonic stemness which is part of the signature of
colorectal CSCs [28,29]. Mechanistically, it might there-
fore be assumed that both b-catenin and SOX2 drive
the malignant progression of CCs by inducing cancer
stemness of colorectal tumour cells. CSCs are known to
be responsible for the process of metastasis [30].
This is also supported by our finding that SOX2
expression can be found within the stem cell niche in
a small proportion of normal colonic crypts (Figure 2).
The fact, that SOX2 plays a major role for the devel-
opment of the upper but not of the lower digestive
tract may explain why SOX2 protein-expression can
only be found in a minority of cases within the normal
colonic tissue. This finding is concordant to previously
published data [19,21]. To further investigate this issue
we correlated the SOX2 expression with previously
published data on CD133, an established marker for
CSC which is predictive for poor prognosis and distant
spread in CC [31-33]. Unexpectedly, no significant cor-
relation between SOX2 and CD133 expression could
be demonstrated in our collection on CC (c
2-test, data
not shown). However, similar to b-catenin combined
Figure 2 Immunohistochemical staining of SOX2 in normal
colonic mucosa. Normal colonic mucosa with absent SOX2
expression (A, 200-fold magnification). Few cases (4%) reveal a
positive SOX2 expression within the stem-cell niche of the colonic
crypt (B, 630-fold). Also adjacent to positive tumour cell infiltrates
no SOX2 expression could be detected in the normal colonic
mucosa in the majority of cases (C, 200-fold).
Table 3 Correlation of SOX2 protein expression and
nuclear and cytoplasmic b-catenin protein expression in
the matched case-control collection of 114 CC patients.
Percent-values are given in parentheses.
SOX-2
high low p
b-catenin (cytoplasmic)
Score 0 0 (0) 0 (0) 0.462
Score 1 2 (1.8) 8 (7.0)
Score 2 8 (7.0) 42 (36.8)
Score 3 14 (12.3) 40 (35.1)
low (0 + 1) 2 (1.8) 8 (7.0) 0.932
high (2 + 3) 22 (19.3) 82 (71.9)
b-catenin (nuclear)
Score 0 6 (5.3) 29 (25.4) 0.897
Score 1 10 (8.8) 31 (27.2)
Score 2 5 (4.4) 19 (16.7)
Score 3 3 (2.6) 11 (9.6)
low (0 + 1) 16 (14.0) 60 (52.6) 1.0
high (2 + 3) 8 (7.0) 30 (26.3)
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predictive value according to the risk of distant spread
(8 of 10 cases; 80%) and the presence of lymph-node
metastases (9 of 10 cases; 90%). In summary, our data
underline the importance of stemness-associated mar-
kers for the prediction of distant spread and the prog-
nostification of CC. These observations also indicate
that markers and marker-combinations for a stemness
phenotype could be relevant for identification of CCs
with high risk for distant spread and subsequently
could have major impact on clinical decisions accord-
ing to the radicalness of loco-regional surgery and
adjuvant chemotherapy.
Through in vitro studies it was shown that SOX2
represses the transcriptional activity of the b-catenin/
TCF complex, thus affecting the expression of onco-
genic b-catenin driven transcription [18,21,22]. The
assumed underlying mechanism, as far as already under-
stood, is complex as SOX2 directly binds to the b-cate-
nin/TCF complex and vice versa SOX2 transcription is
regulated by b-catenin [34-36]. Moreover, knockdown of
SOX2 decreased the growth rate of cultivated colorectal
tumour cell lines in vitro and in vivo [37]. Surprisingly,
no correlation of SOX2 and b-catenin protein expres-
sion levels could be demonstrated in our collection of
CRCs. Nevertheless, it could not be concluded from our
results that the reported negative regulatory feedback
between b-catenin and SOX2 does not occur in human
CRC [34,38-40]. Therefore, to clarify this issue, further
immunohistochemical and functional studies involving
SOX2 and Wnt-regulated target genes are needed to
elaborate the actual impact of the regulatory feedback
mechanisms between SOX2 and the b-catenin/TCF-
complex in CRC patients.
Taken together, our results suggest that SOX2 protein
e x p r e s s i o nm a yb eap o s s i b l ep r o g n o s t i cm a r k e ri nt h e
management of CC patients. Nevertheless, this observa-
tion requires validation in larger, randomized patient
cohorts including also the left side of the colon and the
rectum before SOX2 immunohistochemistry should be
used in the clinical setting.
Conclusion
In summary, we report that overexpression of SOX2 sig-
nificantly correlated with lymph-node and distant
metastases in right-sided CCs. Since both types of
metastases are independent predictors of bad prognosis
our results are in concordance with the reduced survival
reported in the literature. In the same collection, we
revealed that nuclear b-catenin was associated with dis-
tant metastases. Furthermore, coexpression of both mar-
kers was significantly associated with distant spread and
lymph-node metastases in our collection of CCs.
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